Nuvation Bio Inc. (NUVB) stock
NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30105% above fair value
$3.99−0.07 (-1.72%)
Close on Nov 13, 2026Market cap $1.40BP/E –Yield –
Nuvation Bio enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Nuvation Bio's enterprise value was $831.44M on Nov 11, 2026, against $2.17B a year earlier. Over the last 5 years it ranged from -$419.97M to $2.48B, with a median of $202.79M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $831.44M | -66.5% |
| 2025 | Dec 31, 2025 | $2.48B | +602.2% |
| 2024 | Dec 31, 2024 | $353.71M | – |
| 2023 | Dec 29, 2023 | -$288.73M | – |
| 2022 | Dec 30, 2022 | -$254.63M | -124.0% |
| 2021 | Dec 31, 2021 | $1.06B | – |
See a number that looks wrong?